AbbVie [ABBV] vs Gilead Sciences [GILD] Detailed Stock Comparison
AbbVie
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: AbbVie wins in 5 metrics, Gilead Sciences wins in 15 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | AbbVie | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 81.26 | 24.41 | Gilead Sciences |
| Price-to-Book Ratio | 234.48 | 7.34 | Gilead Sciences |
| Debt-to-Equity Ratio | 4,789.60 | 130.79 | Gilead Sciences |
| PEG Ratio | 15.54 | 15.21 | Gilead Sciences |
| EV/EBITDA | 14.54 | 11.42 | Gilead Sciences |
| Profit Margin (TTM) | 7.31% | 20.76% | Gilead Sciences |
| Operating Margin (TTM) | 30.43% | 38.49% | Gilead Sciences |
| EBITDA Margin (TTM) | 30.43% | 38.49% | Gilead Sciences |
| Return on Equity | 88.40% | 32.65% | AbbVie |
| Return on Assets (TTM) | 8.34% | 12.14% | Gilead Sciences |
| Free Cash Flow (TTM) | $17.83B | $10.31B | AbbVie |
| Dividend Yield | 3.44% | 2.84% | AbbVie |
| 1-Year Return | 0.01% | 49.49% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 5.86 | 5.03 | Gilead Sciences |
| Enterprise Value | $397.89B | $156.76B | AbbVie |
| EV/Revenue Ratio | 6.94 | 5.46 | Gilead Sciences |
| Gross Profit Margin (TTM) | 70.01% | 76.90% | Gilead Sciences |
| Revenue per Share (TTM) | $32 | $23 | AbbVie |
| Earnings per Share (Diluted) | $2.32 | $4.63 | Gilead Sciences |
| Beta (Stock Volatility) | 0.48 | 0.31 | Gilead Sciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
AbbVie vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| AbbVie | -1.00% | -0.65% | 1.99% | -2.97% | 7.78% | 5.50% |
| Gilead Sciences | 0.46% | 1.06% | 3.51% | 7.72% | 18.37% | 24.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| AbbVie | 0.01% | 37.14% | 103.73% | 175.88% | 473.67% | 473.67% |
| Gilead Sciences | 49.49% | 87.85% | 65.48% | 0.28% | 540.76% | 976.55% |
Performance & Financial Health Analysis: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $336.11B | $144.55B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 4,787,420 | 5,024,069 |
| 90 Day Avg. Volume | 6,195,300 | 7,151,096 |
| Last Close | $189.31 | $114.76 |
| 52 Week Range | $163.81 - $218.66 | $72.43 - $119.96 |
| % from 52W High | -13.42% | -4.33% |
| All-Time High | $218.66 (Mar 10, 2025) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -13.42% | -6.98% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.00% |
| Quarterly Earnings Growth | -0.06% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.21% |
| Operating Margin (TTM) | 0.30% | 0.38% |
| Return on Equity (TTM) | 0.88% | 0.33% |
| Debt to Equity (MRQ) | 4,789.60 | 130.79 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.80 | $15.39 |
| Cash per Share (MRQ) | $2.93 | $7.00 |
| Operating Cash Flow (TTM) | $16.40B | $10.37B |
| Levered Free Cash Flow (TTM) | $16.94B | $9.99B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.44% | 2.84% |
| Last 12-Month Dividend | $6.38 | $3.12 |
Valuation & Enterprise Metrics Analysis: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 81.26 | 24.41 |
| Forward P/E | 15.54 | 15.21 |
| PEG Ratio | 15.54 | 15.21 |
| Price to Sales (TTM) | 5.86 | 5.03 |
| Price to Book (MRQ) | 234.48 | 7.34 |
| Market Capitalization | ||
| Market Capitalization | $336.11B | $144.55B |
| Enterprise Value | $397.89B | $156.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.94 | 5.46 |
| Enterprise to EBITDA | 14.54 | 11.42 |
| Risk & Other Metrics | ||
| Beta | 0.48 | 0.31 |
| Book Value per Share (MRQ) | $0.80 | $15.39 |
Financial Statements Comparison: AbbVie vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Revenue/Sales | $13.34B | $6.67B |
| Cost of Goods Sold | $4.00B | $1.54B |
| Gross Profit | $9.34B | $5.13B |
| Research & Development | $2.07B | $1.38B |
| Operating Income (EBIT) | $3.98B | $2.49B |
| EBITDA | $4.65B | $3.28B |
| Pre-Tax Income | $1.66B | $1.65B |
| Income Tax | $372.00M | $334.00M |
| Net Income (Profit) | $1.29B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Cash & Equivalents | $5.18B | $7.93B |
| Total Current Assets | $27.68B | $16.90B |
| Total Current Liabilities | $36.40B | $12.34B |
| Long-Term Debt | $64.53B | $22.15B |
| Total Shareholders Equity | $1.46B | $19.08B |
| Retained Earnings | $-9.53B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ABBV | GILD |
|---|---|---|
| Operating Cash Flow | $2.26B | $1.56B |
| Capital Expenditures | $-235.00M | $-104.00M |
| Free Cash Flow | $1.40B | $1.65B |
| Debt Repayment | $-3.03B | $-1.76B |
| Common Stock Repurchase | $-961.00M | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ABBV | GILD |
|---|---|---|
| Shares Short | 15.61M | 22.54M |
| Short Ratio | 2.23 | 2.80 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 4,787,420 | 5,024,069 |
| Average Daily Volume (90 Day) | 6,195,300 | 7,151,096 |
| Shares Outstanding | 1.77B | 1.25B |
| Float Shares | 1.76B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.75% | 0.90% |
Dividend Analysis & Yield Comparison: AbbVie vs Gilead Sciences
| Metric | ABBV | GILD |
|---|---|---|
| Last 12-Month Dividend | $6.38 | $3.12 |
| Last 12-Month Dividend Yield | 3.44% | 2.84% |
| 3-Year Avg Annual Dividend | $6.07 | $3.04 |
| 3-Year Avg Dividend Yield | 0.95% | 0.93% |
| 3-Year Total Dividends | $18.22 | $9.12 |
| Ex-Dividend Date | Apr 15, 2025 | Jun 13, 2025 |